Crystalline pharmaceutical
AssigneeAbbott Laboratories
InventorsDaniel A. Dickman, Sanjay Chemburkar, James J. Fort, Rodger F. Henry, David Lechuga-Ballesteros, Yuping Niu, William Porter
Life of this patent
Estimating the term…
Abstract
New crystalline forms of lopinavir are disclosed.
Claims7
The non-solvated crystalline form of the compound (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl))amino-1,6-diphenylhexane with a peak in the solid state infrared spectrum at a position within the range 1680-1685 cm−1 and a peak in the solid state infrared spectrum at a position within the range 1625-1630 cm−1.
The non-solvated crystalline form of the compound (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)amino-1,6-diphenylhexane with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of 6.85°±0.1°, 9.14°±0.1°, 12.88°±0.1°, 15.09°±0.1°, 17.74°±0.1°, 18.01°±0.1° and 18.53°±0.1°.
The non-solvated crystalline form of the compound (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)amino-1,6-diphenylhexane with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of 6.85°±0.1°, 9.14°±0.1°, 10.80°±0.1°, 12.04°±0.1°, 12.88°±0.1°, 15.09°±0.1°, 17.74°±0.1°, 18.01°±0.1°, 18.26°±0.1°, 18.53°±0.1°, 20.47°±0.1° and 25.35°±0.1°.
The substantially pure non-solvated crystalline form of the compound (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)amino-1,6-diphenylhexane with a peak in the solid state infrared spectrum at a position within the range 1680-1685 cm−1 and a peak in the solid state infrared spectrum at a position within the range 1625-1630 cm−1.
The substantially pure non-solvated crystalline form of the compound (2S,3S ,5S )-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)amino-1,6-diphenylhexane with a peak in the solid state infrared spectrum at a position within the range 1680-1685 cm−1 and a peak in the solid state infrared spectrum at a position within the range 1668-1674 cm−1 and a peak in the solid state infrared spectrum at a position within the range 1656-1662 cm−1 and a peak in the solid state infrared spectrum at a position within the range 1642-1648 cm−1 and a peak in the solid state infrared spectrum at a position within the range 1625-1630 cm−1.
The substantially pure non-solvated crystalline form of the compound (2S,3S ,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)amino-1,6-diphenylhexane with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of 6.85°±0.1°, 9.14°±0.1°, 12.88°±0.1°, 15.09°±0.1°, 17.74°±0.1°, 18.01°±0.1° and 18.53°±0.1°.
The substantially pure non-solvated crystalline form of the compound (2S,3S ,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)amino-1,6-diphenylhexane with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of 6.85°±0.1°, 9.14°±0.1°, 10.80°±0.1°, 12.04°±0.1°, 12.88°±0.1°, 15.09°±0.1°, 17.74°±0.1°, 18.01°±0.1°, 18.26°±0.1°, 18.53°±0.1°, 20.47°±0.1° and 25.35°±0.1°.
Dependencies are inferred from the claim text.